Stockscreener 앱 받기
10.13
2.74%
0.27
전일 마감가:
$9.86
열려 있는:
$9.86
하루 거래량:
1.16M
Relative Volume:
0.94
시가총액:
$807.93M
수익:
$204.89M
순이익/손실:
$-157.30M
주가수익비율:
-4.7984
EPS:
-2.1111
순현금흐름:
$-97.76M
1주 성능:
+5.63%
1개월 성능:
-19.57%
6개월 성능:
-30.52%
1년 성능:
+115.99%
1일 변동 폭
$9.77
$10.21
1주일 범위
$8.78
$10.72
52주 변동 폭
$4.71
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
명칭
Phathom Pharmaceuticals Inc
전화
(877) 742-8466
주소
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
10.13 | 786.39M | 204.89M | -157.30M | -97.76M | -2.1111 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-12-12 | 개시 | Raymond James | Strong Buy |
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 개시 | Stifel | Buy |
| 2024-01-05 | 재확인 | Needham | Buy |
| 2023-08-09 | 개시 | H.C. Wainwright | Buy |
| 2023-05-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-05-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2021-05-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2021-02-17 | 개시 | BMO Capital Markets | Outperform |
| 2021-02-02 | 개시 | Guggenheim | Buy |
| 2020-06-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-11-20 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Goldman | Neutral |
| 2019-11-19 | 개시 | Jefferies | Buy |
| 2019-11-19 | 개시 | Needham | Buy |
모두보기
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
(PHAT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Phathom Pharmaceuticals honors Tachi Yamada legacy in GI medicine - Traders Union
PHAT Stock Price, Quote & Chart | PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) - ChartMill
Phathom Pharmaceuticals shows negative capital efficiency, destroying value amid high R&D costs. - Pluang
[Form 4] Phathom Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Phathom Pharmaceuticals to engage investors at multiple conferences in May and June - Traders Union
How (PHAT) Movements Inform Risk Allocation Models - Stock Traders Daily
PHAT SEC FilingsPhathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Phathom Pharmaceuticals (PHAT) Slips 2.16% as Stock Tests Key Support LevelsOBV Divergence - thelegaladvocate.com
Hear Phathom at three upcoming healthcare investor conferences - Stock Titan
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Phathom (NASDAQ: PHAT) director gains shares via options and RSUs - Stock Titan
Phathom (PHAT) director James Topper receives 24,122 RSUs in equity grant - Stock Titan
Director Mark Stenhouse awarded 24,122 RSUs at Phathom (PHAT) - Stock Titan
Director at Phathom Pharmaceuticals (PHAT) granted 24,122 RSUs - Stock Titan
Director Michael Cola (PHAT) receives 24,122 RSUs in equity award grant - Stock Titan
Director Frank Karbe receives 24,122 RSUs at Phathom (NASDAQ: PHAT) under board compensation plan - Stock Titan
Director Theodore Schroeder (PHAT) receives 24,122 RSU award under non-employee plan - Stock Titan
Phathom Pharmaceuticals (NASDAQ: PHAT) reports 2026 annual meeting vote outcomes - Stock Titan
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting - The Manila Times
Stomach drug vonoprazan draws 28 independent studies at DDW 2026 - Stock Titan
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Analyst Reiterates Buy on Phathom as Voquezna Strategy Advances; $28 Price Target Maintained - TipRanks
Trading Systems Reacting to (PHAT) Volatility - Stock Traders Daily
TradingKey - TradingKey
Number of shareholders of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT - TradingView
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Phathom Pharmaceuticals CEO drives new momentum after DDW2026 to advance GI patient care - Traders Union
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline - Yahoo Finance
Phathom outlines $320M-$345M 2026 revenue as it targets operating profitability by Q3 - MSN
How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing - Stock Traders Daily
147,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Hussman Strategic Advisors Inc. - MarketBeat
How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks - Yahoo Finance
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX) - The Globe and Mail
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call - The Globe and Mail
Earnings call transcript: Phathom Pharmaceuticals beats Q1 2026 EPS expectations - Investing.com Australia
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5%Should You Buy? - MarketBeat
A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $25 to $28 - Moomoo
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2026 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals announces DDW2026 booth and team participation in Chicago - Traders Union
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting - The Manila Times
GERD drug VOQUEZNA gets 3 posters and a May 4 presentation at DDW - Stock Titan
Phathom Pharmaceuticals Inc (PHAT) Q1 2026 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals Reports Q1 2026 Results: VOQUEZNA Prescriptions Surge, Revenue Doubles, Operating Profitability Expected in Q3 - Minichart
Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Phathom Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PHAT) 2026-04-30 - Seeking Alpha
Phathom Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Phathom Pharmaceuticals, Inc. (PHAT) reports Q1 loss, tops revenue estimates - MSN
Phathom (PHAT) Q1 2026 Earnings Transcript - The Globe and Mail
Phathom Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals Inc (PHAT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Phathom Pharmaceuticals Inc 주식 (PHAT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Jan 13 '26 |
Option Exercise |
10.30 |
8,750 |
90,125 |
131,000 |
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
1.13%
3.22%
자본화:
|
볼륨(24시간):